Overview

A Study of Pasireotide in People With Prolactinoma

Status:
RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
RECORDATI GROUP
Treatments:
4-amino-4'-hydroxylaminodiphenylsulfone
pasireotide